• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重复给予κ阿片受体激动剂 U69593 可逆转增强的 K+诱导伏隔核多巴胺释放,但不能逆转安非他命敏化大鼠的运动敏化表达。

Repeated treatment with the kappa opioid receptor agonist U69593 reverses enhanced K+ induced dopamine release in the nucleus accumbens, but not the expression of locomotor sensitization in amphetamine-sensitized rats.

机构信息

Millenium Science Nucleus in Stress and Addiction, Pontificia Universidad Católica de Chile, Santiago, Chile.

出版信息

Neurochem Int. 2012 Mar;60(4):344-9. doi: 10.1016/j.neuint.2012.01.014. Epub 2012 Jan 28.

DOI:10.1016/j.neuint.2012.01.014
PMID:22306346
Abstract

The effects after the acute activation of the kappa opioid receptor (KOR) can be distinguished from the effect after repeated administration of KOR agonist. Here, we report the effect of repeated administration of U69593 during abstinence after amphetamine-induced locomotor sensitization. Rats were injected once daily with amphetamine for five consecutive days. From day 6 to 9, rats that developed locomotor sensitization, received once daily injection of U69593 or vehicle. On day 10, all rats were injected with a challenging dose of amphetamine and locomotor activity was measured to assess the expression of sensitization. Microdialysis studies were carried out to assess dopamine extracellular levels in NAc. Rats that develop and express horizontal locomotor sensitization to amphetamine show increased dopamine release in the NAc induced by high K(+). The repeated treatment with U69593 reverses the sensitized depolarization-stimulated dopamine release in the NAc, but not the expression of locomotor sensitization induced by amphetamine. Thus, repeated activation of KORs during early amphetamine withdrawal dissociates the behavioral responses and the neurochemical responses that accompany the expression of sensitization to amphetamine.

摘要

κ 阿片受体(KOR)的急性激活后的影响与 KOR 激动剂重复给药后的影响不同。在这里,我们报告了在安非他命诱导的运动敏化戒断期间重复给予 U69593 的效果。大鼠每天接受安非他命注射一次,连续五天。从第 6 天到第 9 天,对出现运动敏化的大鼠,每天给予 U69593 或载体注射。第 10 天,所有大鼠均接受安非他命的挑战剂量注射,并测量运动活动以评估敏化的表达。微透析研究用于评估 NAc 中的多巴胺细胞外水平。对安非他命产生和表达水平运动敏化的大鼠,在 NAc 中显示出由高 K+诱导的多巴胺释放增加。U69593 的重复治疗逆转了 NAc 中敏化的去极化刺激的多巴胺释放,但不能逆转安非他命诱导的运动敏化的表达。因此,在安非他命早期戒断期间,重复激活 KORs 可分离伴随安非他命敏化表达的行为反应和神经化学反应。

相似文献

1
Repeated treatment with the kappa opioid receptor agonist U69593 reverses enhanced K+ induced dopamine release in the nucleus accumbens, but not the expression of locomotor sensitization in amphetamine-sensitized rats.重复给予κ阿片受体激动剂 U69593 可逆转增强的 K+诱导伏隔核多巴胺释放,但不能逆转安非他命敏化大鼠的运动敏化表达。
Neurochem Int. 2012 Mar;60(4):344-9. doi: 10.1016/j.neuint.2012.01.014. Epub 2012 Jan 28.
2
Increased responsiveness of mesolimbic and mesostriatal dopamine neurons to cocaine following repeated administration of a selective kappa-opioid receptor agonist.在反复给予选择性κ-阿片受体激动剂后,中脑边缘和中脑纹状体多巴胺神经元对可卡因的反应性增强。
Synapse. 1998 Nov;30(3):255-62. doi: 10.1002/(SICI)1098-2396(199811)30:3<255::AID-SYN3>3.0.CO;2-A.
3
Repeated administration of the selective kappa-opioid receptor agonist U-69593 increases stimulated dopamine extracellular levels in the rat nucleus accumbens.选择性κ-阿片受体激动剂U-69593的重复给药可增加大鼠伏隔核中刺激的多巴胺细胞外水平。
J Neurosci Res. 2006 Aug 1;84(2):450-9. doi: 10.1002/jnr.20890.
4
Modulation of pre- and postsynaptic dopamine D2 receptor function by the selective kappa-opioid receptor agonist U69593.选择性κ-阿片受体激动剂U69593对突触前和突触后多巴胺D2受体功能的调节
Synapse. 2001 Mar 15;39(4):343-50. doi: 10.1002/1098-2396(20010315)39:4<343::AID-SYN1018>3.0.CO;2-Q.
5
Increased locomotor response to amphetamine induced by the repeated administration of the selective kappa-opioid receptor agonist U-69593.重复给予选择性κ-阿片受体激动剂U-69593后,对苯丙胺的运动反应增强。
Synapse. 2007 Sep;61(9):771-7. doi: 10.1002/syn.20424.
6
Mechanisms of Kappa Opioid Receptor Potentiation of Dopamine D2 Receptor Function in Quinpirole-Induced Locomotor Sensitization in Rats.κ 阿片受体增强大鼠喹吡罗诱导的运动性敏感中多巴胺 D2 受体功能的机制。
Int J Neuropsychopharmacol. 2017 Aug 1;20(8):660-669. doi: 10.1093/ijnp/pyx042.
7
Repeated treatment with the κ-opioid agonist U-69593 increases K+-stimulated dopamine release in the rat medial prefrontal cortex.反复给予 κ-阿片受体激动剂 U-69593 可增加大鼠内侧前额叶皮层中 K+刺激的多巴胺释放。
Synapse. 2010 Dec;64(12):898-904. doi: 10.1002/syn.20808.
8
Dissociable effects of the kappa-opioid receptor agonists bremazocine, U69593, and U50488H on locomotor activity and long-term behavioral sensitization induced by amphetamine and cocaine.κ-阿片受体激动剂布马佐辛、U69593和U50488H对苯丙胺和可卡因诱导的运动活性及长期行为敏化的不同作用。
Psychopharmacology (Berl). 2000 May;150(1):35-44. doi: 10.1007/s002130000424.
9
Kappa-opioid agonist U69593 potentiates locomotor sensitization to the D2/D3 agonist quinpirole: pre- and postsynaptic mechanisms.κ-阿片受体激动剂U69593增强对D2/D3激动剂喹吡罗的运动敏化:突触前和突触后机制。
Neuropsychopharmacology. 2006 Sep;31(9):1967-81. doi: 10.1038/sj.npp.1300938. Epub 2005 Oct 12.
10
Cotreatment with the kappa opioid agonist U69593 enhances locomotor sensitization to the D2/D3 dopamine agonist quinpirole and alters dopamine D2 receptor and prodynorphin mRNA expression in rats.与κ阿片受体激动剂U69593联合治疗可增强大鼠对D2/D3多巴胺激动剂喹吡罗的运动敏化作用,并改变多巴胺D2受体和前强啡肽mRNA的表达。
Psychopharmacology (Berl). 2007 Nov;194(4):485-96. doi: 10.1007/s00213-007-0855-3. Epub 2007 Jul 10.

引用本文的文献

1
Relevance of the Kappa Dynorphin System to Schizophrenia and Its Therapeutics.κ-强啡肽系统与精神分裂症及其治疗的相关性
J Psychiatr Brain Sci. 2021;6. doi: 10.20900/jpbs.20210015. Epub 2021 Aug 24.
2
Adolescent Exposure to WIN 55212-2 Render the Nigrostriatal Dopaminergic Pathway Activated During Adulthood.青少年期暴露于 WIN 55212-2 会导致成年期黑质纹状体多巴胺能通路激活。
Int J Neuropsychopharmacol. 2020 Dec 3;23(9):626-637. doi: 10.1093/ijnp/pyaa053.
3
Crosstalk Between Kappa Opioid and Dopamine Systems in Compulsive Behaviors.
强迫行为中κ阿片系统与多巴胺系统之间的相互作用
Front Pharmacol. 2020 Feb 18;11:57. doi: 10.3389/fphar.2020.00057. eCollection 2020.